Dr. Robert Huizinga reports

KANE BIOTECH EXPANDS CANADIAN COMMERCIAL REACH WITH ONTARIO MEDICAL SUPPLY INC.

Kane Biotech Inc. has entered into a non-exclusive distribution agreement with Ontario Medical Supply Inc. (OMS), an Ottawa-based medical supply distributor serving the Canadian market.

Under the agreement, OMS will purchase Kane's U.S. FDA 510(k)-cleared and Health Canada-approved revyve anti-microbial wound gel and revyve anti-microbial wound gel spray and market and support the products through its wound care sales activities. Kane will provide approved product training and sales materials.

The agreement positions OMS to support access to revyve in a large and clinically demanding segment of the Canadian wound care market. As one of only two authorized distributors and price agreement holders for Ontario Health atHome, OMS plays an important role in enabling manufacturer access to the Ontario Health atHome formulary. Ontario Health atHome, the provincial organization responsible for co-ordinating publicly funded home and community care services, including home-care nursing and long-term care placement, provides care to more than 680,000 patients across Ontario annually and delivered 11.1 million nursing visits in the province in 2024/2025. Published estimates suggest that wound care may account for approximately 40 to 50 per cent of home-care nursing visits, with Wounds Canada similarly noting that approximately 50 per cent of home-care visits involve wound care. Together, these data underscore the significant clinical and resource burden associated with treating acute, chronic and complex wounds across the province.

The addition of OMS supports Kane's strategy to expand access to revyve across Canada through experienced distribution partners. The agreement gives OMS a non-exclusive right to sell the products in Canada and establishes a framework for product ordering, training, customer support, quality management, traceability and complaint reporting.

"Expanding our Canadian distribution network is an important part of making revyve more accessible to clinicians and care providers," said Dr. Robert Huizinga, interim chief executive officer of Kane Biotech. "OMS brings established medical supply capabilities and wound care market experience. This agreement strengthens our route to market in Canada and supports our focus on converting broader access into sustainable product adoption."

Kane's revyve product line is designed to address both biofilms and wound bacteria. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are U.S. FDA 510(k) cleared and Health Canada approved.

About Kane Biotech Inc.

Kane Biotech is commercializing and developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds, resulting in serious clinical outcomes and significant cost. revyve addresses both biofilms and wound bacteria. revyve anti-microbial wound gel, revyve anti-microbial wound gel spray and revyve anti-microbial skin and wound cleanser are all U.S. FDA 510(k) cleared. revyve anti-microbial wound gel and revyve anti-microbial wound gel spray are also Health Canada approved.

We seek Safe Harbor.